NCT02941991View on ClinicalTrials.gov

A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

CompletedOBSERVATIONAL
Enrollment

12

Participants

Timeline

Start Date

January 16, 2013

Primary Completion Date

October 2, 2019

Study Completion Date

October 2, 2019

Conditions
Stargardt's Macular Dystrophy
Interventions
BIOLOGICAL

hESC-RPE

sub-retinal injection

Trial Locations (2)

EC1V2PD

Moorefields Eye Hospital NHS Foundation Trust, London

NE7 7DN

Newcastle on Tyne NHS Foundation Trust, Newcastle upon Tyne

All Listed Sponsors
lead

Astellas Institute for Regenerative Medicine

INDUSTRY

NCT02941991 - A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | Biotech Hunter | Biotech Hunter